{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '7. ABSTRACT', 'Study title: Patient-Reported outcomes in rheumatoid arthritis patients treated with tofacitinib or biological', 'disease-modifying antirheumatic drugs (DMARDs) in real life conditions', 'Protocol Number', 'A3921284', 'Phase', '4', 'Type', 'Observational', 'Condition/Disease', 'People with Rheumatoid Arthritis', 'Number of subjects', '320 patients', 'Permanence of subjects in', '6 months', 'the study', 'Participant', 'countries', 'Colombia (11), Peru (4),', 'Duration of study', '16 months', '(number of sites)', 'Ecuador (1)', 'Rational', 'Biological therapies are drugs that emerged almost a decade ago for preventing or reducing the swelling', 'caused by Rheumatoid Arthritis (RA) after failure from a conventional drug such as methotrexate (MTX).', 'These are molecules consisting of proteins produced by living organisms that act on very specific mechanisms', 'of a cell, organ or system (1-4)', 'Furthermore, there are also chemically synthesized molecules produced from chemical precursors for the', 'treatment of arthritis; tofacitinib is a chemically synthesized drug targeted to block the pathway of an enzyme', \"called Janus kinase (JAK), involved in body's immune response, and fighting swelling from inside the cell.\", 'Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib 5 mg twice daily (BID) and', 'tofacitinib 10 mg BID have demonstrated consistent efficacy in reducing the signs and symptoms of RA, and', 'showed improvements in the Patient-Reported Outcomes (PROs), with manageable safety profiles across six', 'Phase 3 studies, either as monotherapy or in combination with conventional disease-modifying antirheumatic', 'drugs (DMARDs) (5-10).', 'Although there are several studies for the assessment of efficacy (including patient reported outcomes) and', 'safety of tofacitinib compared with placebo or methotrexate in the treatment of RA, there is limited', 'information on its use in current practice in Latin America. Additionally, there are no data comparing', 'tofacitinib with biological DMARDs directly in real conditions. Studies focusing on these comparisons are of', 'great importance for all physicians involved in the management of RA patients.', 'Additionally, tofacitinib safety profile has demonstrated to be consistent in long-term extension studies (11).', 'In the indirect comparison, tofacitinib has a similar safety profile to biological DMARDs. However, Latin-', 'American physicians expect to see similar results with their patients.', 'Objectives', 'The objective of this study is to describe the outcomes related to physical activity, activity of disease, quality', 'of life, work productivity and safety in Latin-American patients with RA treated with tofacitinib or biological', 'DMARDs after failure to respond to conventional DMARDs in real-life conditions.', 'Study design', 'This will be a non-interventional, hybrid study (prospective and retrospective data collection) comparing', 'tofacitinib to biologic DMARD treatments in patients with RA after failure of conventional DMARDs, in', 'second line of therapy.', 'Inclusion criteria:', 'Patients > 18 years of age at the time of recruitment', 'Patient diagnosed with moderate to severe RA > 6 months before enrollment', 'Patients with DAS28 score > 3.2', 'Patients who have had an inadequate response to the continuous use of methotrexate or combination of', 'conventional DMARDs for at least 12 weeks before the study without dose change within the last 8', 'weeks before enrollment in the study.', 'Page 13 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'Patients with no biological DMARDs use in patient history.', 'Patients prescribed with tofacitinib or biological DMARDs in the last two weeks at doses established in', 'ACR guidelines published in 2015 and following medical criteria.', 'Acceptance for patients to participate in the study and signing of the informed consent.', 'Exclusion criteria:', 'Patients who do not have the ability to answer the questionnaires by themselves or who have any kind of', 'mental disorder that may affect their answers.', \"Patients diagnosed with autoimmune rheumatic diseases other than RA and Sjogren's syndrome.\", 'Patients treated with biological DMARDs in monotherapy.', 'Participation in other studies involving investigational drug(s) (Phases 1-4) within 4 weeks or 5 half-lives', '(whichever is longer) after discontinuation of the investigational compound before the current study', 'begins and/or during study participation.', 'Pregnant or breastfeeding women.', 'Patients with any current malignancy or a history of malignancy, with the exception of adequately treated', 'or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.', 'Patients with lymphoproliferative disorders (e.g., Epstein Barr Virus (EBV) related lymphoproliferative', 'disorder), a history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic', 'disease.', 'Recruitment mode:', 'Convenience sampling in the tofacitinib arm and randomized in the biological DMARD arm will be', 'performed', 'Randomized recruitment into the arm of tofacitinib cannot be used because of the low group of patients with', 'the drug.', 'Data collection:', 'The information may only be collected once the protocol has been approved by Pfizer and the Ethics', 'Committee of the sites, training on adverse events (AE) reporting has been provided, and the informed', 'consent form has been signed by the parties. After the potential patients to be included in the study are', 'identified, the treating physician (rheumatologist) will verify the inclusion/exclusion criteria for determining', 'the patient eligibility and will complete the baseline information.', 'The investigator will apply health assessment questionnaires at the beginning of recruitment (month zero) and', 'Month 6 of follow-up. Before sending the information to Pfizer in a standard form for subsequent analysis,', 'data from patients must be codified and verified by the CRO to assure that we will receive complete', 'information and that patients would not be identified by Pfizer.', 'Outcomes', '-', 'Information reported by patients (Patient Reported Outcomes [PRO]) on disease activity, functional', 'status, quality of life and work productivity.', '-', 'Frequency of adverse events.', 'Data sources:', 'Patients, through application of PROs:', '-', 'Routine Assessment of Patients Index Data (RAPID3) and DAS28: Disease activity', '-', 'Adapted Health Assessment Questionnaire (HAQ-DI): Functional status', '-', 'EuroQol Questionnaire (EQ-5D): Quality of life', '-', 'Work Productivity and Activity Impairment (WPAI): Work productivity', '-', 'Spontaneously reported safety information', 'Medical records', 'Page 14 of 64']\n\n###\n\n", "completion": "END"}